Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination
Arkenau, H Voskoboynik, M Infante, J Brenner, A Patel, M Borazanci, E Falchook, G Molife, L Molife, L Pelosof, L
Arkenau, H
Voskoboynik, M
Infante, J
Brenner, A
Patel, M
Borazanci, E
Falchook, G
Molife, L
Molife, L
Pelosof, L
Citations
Altmetric:
Abstract
Description
Date
2015
Publisher
Collections
Keywords
Type
Article
Citation
Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. 2015 51 S724-S724 Eur J Cancer